We based our review on a narrative rather than systematic literature search. We searched MEDLINE for papers published in the English language before March 31, 2019, on treatment and stratification of therapies in IgG4-related disease. We identified key abstracts from the European League Against Rheumatism and American College of Rheumatology annual meetings in 2016–18. Search terms were “IgG4-related disease”, “autoimmune pancreatitis”, “tubulointerstitial nephritis”, “complement”, “SLAMF7”, “B
ReviewManagement of IgG4-related disease
Introduction
IgG4-related disease is a multi-organ, immune-mediated condition that was recognised as a unified disease only in 2003.1, 2 However, clinical presentations now known to be classic features of IgG4-related disease appeared in the medical literature much earlier, with descriptions in the late 1800s of Mikulicz disease (simultaneous enlargement of the lacrimal and major salivary glands);3 Küttner's tumour (isolated submandibular gland enlargement);4 and Riedel's thyroiditis.5 Many of the other organ system manifestations now linked to IgG4-related disease were identified during the 1900s, but these were thought to be manifestations of single-organ diseases'6 or processes restricted to single-body regions,7 rather than parts of a systemic inflammatory disease. The connection between clinical features of disease and elevated serum concentrations of IgG4 was established in 2000, when Hamano and colleagues8 reported the utility of elevated serum IgG4 concentrations in distinguishing between sclerosing pancreatitis—now known as type 1 IgG4-related autoimmune pancreatitis—and other hepatobiliary conditions.
In the past decade, there has been an extraordinary expansion in knowledge about IgG4-related disease. Furthermore, the indolent nature of the disease and the use of targeted treatment approaches have provided major insights into its pathophysiology. These insights, in turn, suggest the possibility of several mechanism-based approaches to therapy. In this review, we discuss the pathology and pathophysiology of IgG4-related disease and provide an overview of the clinical management of patients with the disease.
Section snippets
Pathology and pathophysiology
The organs affected by IgG4-related disease all share similar histopathological and immunostaining features.9 The hallmark findings include a dense lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells (figure 1A). This cellular infiltrate is enmeshed in fibrosis with an irregular, whorled appearance termed storiform fibrosis (figure 1B).10 Obliterative phlebitis and eosinophilic infiltration are observed in approximately half of patients with IgG4-related disease. By contrast,
Clinical characteristics of disease
IgG4-related disease affects nearly every organ, but particularly the meninges, orbits (extraocular muscles and retrobulbar masses), lacrimal glands, salivary glands, thyroid gland, pancreas, bile ducts, lungs, kidneys, aorta, and retroperitoneum. Approximately 40% of patients present with clinically-evident disease in a single organ, but presentations involving five or six organs are not uncommon. Moreover, the disease can evolve over time, with new organs becoming involved in a metachronous
Disease classification and subsets
Classifying IgG4-related disease into distinct subsets is intuitively appealing because the identification of disease subsets and their corresponding biological features might lead to insights that guide treatment. The ultimate utility of identifying disease subsets is to discover meaningful biological differences between subsets that offer insights into prognosis or guide therapy.
The American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) have produced a
Biomarkers
Studies in IgG4-related disease benefit from a wealth of good potential biomarkers, some of which are useful in clinical management. Serum IgG4 concentrations—which are elevated in most patients—have proven particularly useful. In many patients with elevated serum IgG4 concentrations at baseline, trends in IgG4 concentrations over time constitute a reliable biomarker of disease activity and an indicator of when re-treatment should be considered. Moreover, serum IgG4 concentrations reflect the
Risk factors for relapse
Risk factors for disease relapse can be divided into five main categories: demographic features, organ involvement, serological findings, medications, and changes in peripheral blood cell populations. Reported risk factors for relapse are shown in figure 3, organised according to their frequency as reported in the literature.
Being male has been implicated as a risk factor for disease flare in some studies, with a hazard ratio of 3·14 (p=0·003) reported in one study.74 This is interesting in
Special situations
In selected situations, surgical treatment or other mechanical interventions (eg, stent placement) are complementary approaches to medical therapy. Surgical biliary drainage, now rare, was common before IgG4-related disease was recognised as a specific disease entity. Surgical resection of some organs that are severely damaged is occasionally necessary. The placement of biliary stents, ureteral stents, or nephrostomy tubes are sometimes required at the start of medical therapy, but ideally, the
Future Steps
In less than 15 years, IgG4-related disease has gone from being an unrecognised disease to one that is recognised around the world. The disease has certain strong organ predilections, and clinicians from nearly every specialty now recognise the complications of IgG4-related disease within their fields. IgG4-related disease is one of the great mimickers of other diseases in the current era, and early recognition and treatment is crucial. Areas of uncertainty, ongoing controversy, and intense
Search strategy and selection criteria
References (82)
- et al.
Autoimmune pancreatitis is a systemic autoimmune disease
Am J Gastroenterol
(2003) Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process
J Urol
(1948)- et al.
Consensus statement on the pathology of IgG4-related disease
Mod Pathol
(2012) - et al.
Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease
J Allergy Clin Immunol Pract
(2016) - et al.
Circulating precursor CCR7(lo)PD-1(hi) CXCR5(+) CD4(+) T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure
Immunity
(2013) - et al.
Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy
Arthritis Res Ther
(2019) - et al.
Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis
Gastrointest Endosc
(2007) - et al.
Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis
Clin Gastroenterol Hepatol
(2009) - et al.
IgG4-related disease
Lancet
(2015) - et al.
Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients
Arthritis Res Ther
(2018)
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy
Gastroenterol
Cutaneous immunoglobulin G4-related systemic disease
Am J Med
Clinical manifestations and long-term outcomes of IgG4-related kidney and retroperitoneal involvement in a United Kingdom IgG4-related disease cohort
Kidney Int Rep
Surgical procedure in immunoglobulin G4-related ascending aortitis?
Ann Thorac Surg
A new clinicopathological entity of IgG4-related autoimmune disease
J Gastroenterol
Über eine eigenartige symmetrische erkränkung der thränen—und mundspeicheldrüsen
Über entzündliche tumoren der submaxillar-speicheldrüse
Beitr Klin Chir
Die chronische zur Bildung eisenharter Tumoren fuhrende Entzündung der Schildrüse
Verhandlung der deutsche Gesellschaft für Chirurgie
A case of exocrine and endocrine pancreatic insufficiency following sclerosing pancreatitis complicating an unusual pancreatic deformity
Frankf Z Pathol
High serum IgG4 concentrations in patients with sclerosing pancreatitis
N Engl J Med
IgG4-related disease
N Engl J Med
Emerging treatment models in rheumatology: IgG4-related disease: insights into human immunology and targeted therapies
Arthritis Rheumatol
SLAM family receptors and SAP adaptors in immunity
Annu Rev Immunol
Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus
Immunity
The expansion in lymphoid organs of IL-4(+) BATF(+) T follicular helper cells is linked to IgG4 class switching in vivo
Life Sci Alliance
Impaired expression of innate immunity-related genes in IgG4-related disease (IgG4-RD): a possible mechanism in the pathogenesis of IgG4-RD
Mod Rheumatol
Identification of galectin-3 as an autoantigen in patients with IgG4-related disease
J Allergy Clin Immunol Pract
Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease
Gut
Laminin 511 is a target antigen in autoimmune pancreatitis
Sci Transl Med
Prohibitin is involved in patients with IgG4 related disease
PLoS One
Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts
Ann Rheum Dis
IgG4-related disease and the kidney
Nat Rev Nephrol
Clinical features of IgG4-related periaortitis/periarteritis based on the analysis of 179 patients with IgG4-related disease: a case-control study
Arthritis Res Ther
Inflammatory features, including symptoms, increased serum interleukin-6, and C-reactive protein, in IgG4-related vascular diseases
Heart Vessels
International consensus guidance statement on the management and treatment of IgG4-related disease
Arthritis Rheumatol
IgG4-related disease: diagnostic methods and therapeutic strategies in Japan
J Clin Exp Hematop
“How I manage” IgG4-Related Disease
J Clin Immunol
Standard steroid treatment for autoimmune pancreatitis
Gut
Necessity of early intervention for IgG4-related disease—delayed treatment induces fibrosis progression
Rheumatol
Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience
Gut
Cited by (98)
Bilateral cervical masses
2023, Revue de Medecine InterneIgG4-related disease as a variable-vessel vasculitis: A case series of 13 patients with medium-sized coronary artery involvement
2023, Seminars in Arthritis and RheumatismIgG4-Related Disease of the Pharynx with Spontaneous Regression
2022, American Journal of MedicineCitation Excerpt :An international consensus guidance has suggested that not all cases require immediate treatment, and watchful waiting may be possible in patients with asymptomatic lymphadenopathy or mild submandibular gland enlargement.8 Close follow-up is recommended because the disease may recur months or years later.9 Several factors have been reported to predict spontaneous remission, such as female sex,3,10 serum C3 levels,10 and absence of serum IgG4 elevation.3
IgG4 disease with multiorgan involvement: a case report
2024, Journal of Medical Case Reports